How to Get Prescribed Wegovy: The Medical Qualification Criteria, Provider Evaluation Process, and What Happens When Insurance Says No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy requires BMI ≥30, or BMI ≥27 with one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• The prescription process involves baseline labs (A1C, lipid panel, TSH, creatinine), cardiovascular risk screening, and documented weight-loss attempts in most clinical protocols
• Insurance approval rates for Wegovy sit at 42% as of Q1 2026, with prior authorization denials most commonly citing "step therapy not completed" or "lifestyle modification not documented"
• When brand-name Wegovy is denied or unavailable, compounded semaglutide offers the same active ingredient at 60-80% lower cost without prior authorization requirements

Direct answer (40-60 words)

To get prescribed Wegovy, you need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. A licensed provider evaluates your medical history, orders baseline labs, confirms no contraindications (personal or family history of medullary thyroid carcinoma or MEN2), and writes the prescription. Insurance coverage requires prior authorization in 94% of commercial plans.

Table of contents

1. The exact BMI and comorbidity thresholds
2. The medical conditions that qualify you at lower BMI
3. The absolute contraindications that disqualify you
4. What providers evaluate during the qualification visit
5. The baseline lab panel and why each test matters
6. The prior authorization process: what insurance companies require
7. What most articles get wrong about "trying diet and exercise first"
8. The three pathways when insurance denies coverage
9. Compounded semaglutide as the functional alternative
10. The FormBlends qualification protocol
11. State-by-state telehealth prescribing rules for GLP-1s
12. When you should NOT pursue Wegovy
13. FAQ
14. Footer disclaimers

The exact BMI and comorbidity thresholds

Wegovy's FDA-approved indication and the clinical criteria most providers follow are identical:

Primary qualification pathway:

• BMI ≥30 kg/m² (classified as obesity)
• No additional conditions required

Secondary qualification pathway:

• BMI ≥27 kg/m² (classified as overweight)
• PLUS at least one of the following weight-related comorbidities:
• Type 2 diabetes mellitus
• Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on statin therapy)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease (prior MI, stroke, or established coronary artery disease)

These thresholds come directly from the STEP trial inclusion criteria (Wilding et al., New England Journal of Medicine, 2021) and match the prescribing information published by Novo Nordisk.

A common question: "Can I qualify with BMI 26.8?" The answer depends on the provider. The FDA label says ≥27. Some providers round; most don't. A BMI of 26.8 with documented hypertension sits in a gray zone. Telehealth platforms with standardized protocols typically enforce the threshold strictly. In-person providers have more discretion.

The medical conditions that qualify you at lower BMI

The five conditions that open the BMI 27-29.9 pathway are not arbitrary. Each has published evidence linking weight loss to disease improvement.

Type 2 diabetes. The STEP 2 trial (Davies et al., Lancet, 2021) enrolled patients with T2D and BMI ≥27. Semaglutide 2.4 mg produced a mean A1C reduction of 1.6% and 9.6% weight loss at 68 weeks. The mechanism is dual: weight loss improves insulin sensitivity, and GLP-1 agonism directly stimulates insulin secretion.

Hypertension. The STEP 1 trial showed systolic blood pressure reductions of 6.2 mmHg in the semaglutide group vs 1.1 mmHg in placebo, independent of blood pressure medication changes (Wilding et al., 2021). Weight loss reduces sympathetic nervous system activity and improves endothelial function.

Dyslipidemia. Semaglutide reduces triglycerides by 12-18% and increases HDL modestly. LDL changes are variable but trend downward with sustained weight loss. The lipid benefit is mostly mediated by weight loss rather than direct drug effect.

Obstructive sleep apnea. Weight loss of 10% reduces apnea-hypopnea index (AHI) by 20-30% in most patients (Schwartz et al., American Journal of Respiratory and Critical Care Medicine, 2008). OSA qualifies you for Wegovy because the relationship is bidirectional: OSA worsens weight gain through sleep disruption and metabolic dysregulation.

Cardiovascular disease. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) demonstrated a 20% reduction in major adverse cardiovascular events in patients with established CVD treated with semaglutide 2.4 mg. This moved semaglutide from "weight-loss drug" to "cardioprotective agent" in the eyes of many cardiologists.

If you have one of these conditions, document it. Insurance prior authorization forms ask for ICD-10 codes. "I think I have sleep apnea" doesn't count. "Diagnosed OSA, AHI 22, on CPAP" does.

The absolute contraindications that disqualify you

Wegovy has two absolute contraindications and several relative ones.

Absolute contraindications (cannot prescribe):

1. Personal history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodent studies. The FDA requires a black-box warning. No human cases have been causally linked to GLP-1 agonists, but the theoretical risk disqualifies anyone with prior MTC.

1. Multiple endocrine neoplasia syndrome type 2 (MEN2). A genetic syndrome that predisposes to MTC. If you or a first-degree relative has MEN2, you cannot take Wegovy.

Relative contraindications (require provider judgment):

• Personal history of pancreatitis. GLP-1 agonists carry a small increased risk of acute pancreatitis (about 1.5 to 2 times baseline). Most providers avoid prescribing to patients with prior pancreatitis unless the benefit clearly outweighs risk.
• Severe gastroparesis. Semaglutide slows gastric emptying. Pre-existing severe gastroparesis can worsen to the point of requiring hospitalization.
• Pregnancy or planning pregnancy. Semaglutide is pregnancy category X (contraindicated). Discontinue at least 2 months before attempting conception.
• Diabetic retinopathy. Rapid glucose lowering in patients with pre-existing retinopathy can transiently worsen retinal disease. The SUSTAIN-6 trial (Marso et al., 2016) showed a small signal. Most endocrinologists still prescribe but monitor closely.
• End-stage renal disease. Semaglutide is renally cleared. ESRD patients can take it, but nausea and GI side effects are more common.

Family history of thyroid cancer (non-MTC types) is not a contraindication. Family history of MTC in a first-degree relative is.

Providers ask about these during intake. Answer honestly. Omitting a contraindication to get a prescription puts you at real medical risk.

What providers evaluate during the qualification visit

Whether you see a provider in person or via telehealth, the evaluation follows a standard structure. Here's what happens.

Medical history review:

• Current medications (to check for drug interactions and duplicative therapies)
• Prior weight-loss attempts (diet programs, medications, bariatric surgery)
• Weight history (highest adult weight, lowest adult weight, recent trends)
• Comorbid conditions (diabetes, hypertension, sleep apnea, PCOS, etc.)
• Contraindication screening (thyroid cancer history, pancreatitis, pregnancy plans)
• Psychiatric history (depression, eating disorders, suicidal ideation)

Physical assessment (in-person or patient-reported for telehealth):

• Height and weight (to calculate BMI)
• Blood pressure
• Heart rate
• Baseline vitals

Cardiovascular risk assessment:

• The SELECT trial results have made CV risk screening standard practice
• Providers ask about prior MI, stroke, peripheral artery disease, or coronary stents
• ASCVD risk score calculation for patients over 40
• Family history of early cardiovascular disease

Baseline laboratory orders:

• Hemoglobin A1C (to screen for undiagnosed diabetes)
• Comprehensive metabolic panel (creatinine for kidney function, ALT/AST for liver)
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• TSH (thyroid function)
• Pregnancy test for women of childbearing age

Most telehealth platforms partner with Quest or LabCorp for lab draws. You get a requisition, visit a local draw site, and results populate in 2 to 4 days. The provider reviews labs before finalizing the prescription.

Informed consent discussion:

• Black-box warning about thyroid C-cell tumors
• Common side effects (nausea, diarrhea, constipation, abdominal pain)
• Rare serious risks (pancreatitis, gallbladder disease, kidney injury)
• Injection technique and storage
• Expectations for weight loss (10-15% over 68 weeks in trials)

The visit typically takes 20 to 40 minutes in person, 15 to 25 minutes via telehealth. Telehealth platforms that use asynchronous intake (you fill out forms, provider reviews, then calls) can compress this to 10 to 15 minutes of live interaction.

The baseline lab panel and why each test matters

The standard pre-Wegovy lab panel includes five tests. Each serves a specific clinical purpose.

Test	Normal range	Why it matters for Wegovy
Hemoglobin A1C	<5.7% (non-diabetic)	Screens for undiagnosed diabetes. If A1C ≥6.5%, you have diabetes, which changes the risk-benefit calculation and may shift the provider toward Ozempic (approved for diabetes) rather than Wegovy.
Creatinine / eGFR	Creatinine 0.6-1.2 mg/dL; eGFR >60	GLP-1 agonists are cleared renally. Impaired kidney function increases drug exposure and side-effect risk. Severe nausea and vomiting can worsen kidney function through dehydration.
ALT / AST	ALT <33 U/L (women), <40 U/L (men)	Screens for liver disease. Rapid weight loss can transiently worsen fatty liver (a paradoxical early effect before improvement). Providers want a baseline.
Lipid panel	LDL <100 mg/dL, triglycerides <150 mg/dL	Documents baseline cardiovascular risk. Weight loss improves lipids, and the provider will recheck at 3 to 6 months to quantify benefit. Also used for insurance prior authorization if dyslipidemia is the qualifying comorbidity.
TSH	0.4-4.0 mIU/L	Screens for hypothyroidism, which can cause weight gain and fatigue. Untreated hypothyroidism blunts weight-loss response to any intervention. Also part of the thyroid cancer contraindication screening.

Some providers add a pregnancy test (required if there's any chance of pregnancy) and a lipase level (baseline pancreatic enzyme to compare against if pancreatitis is suspected later).

The lab panel costs $80 to $150 if you're paying out of pocket. Insurance typically covers it as preventive or diagnostic depending on your plan.

Results outside normal ranges don't automatically disqualify you, but they change the conversation. An A1C of 6.8% means you have diabetes, and the provider may recommend Ozempic (semaglutide for diabetes) instead. A creatinine of 1.8 mg/dL means the provider will start at a lower dose and monitor kidney function closely.

The prior authorization process: what insurance companies require

As of Q1 2026, 94% of commercial insurance plans classify Wegovy as a "prior authorization required" medication. Medicare Part D covers Wegovy as of 2025 under the Treat and Reduce Obesity Act, but also requires prior authorization. Medicaid coverage varies by state (32 states cover GLP-1s for weight loss as of 2026).

What prior authorization means: Your provider writes the prescription and submits a request to your insurance company with supporting documentation. A pharmacist or nurse at the insurance company reviews the request against the plan's coverage criteria. They approve, deny, or request more information. The process takes 2 to 10 business days.

What insurance companies require (typical criteria):

1. BMI documentation. Must meet ≥30, or ≥27 with comorbidity. Requires height, weight, and calculated BMI in the medical record within the past 30 days.

1. Comorbidity documentation (if BMI 27-29.9). ICD-10 codes for diabetes, hypertension, dyslipidemia, or sleep apnea. "Patient reports high blood pressure" doesn't count. Documented diagnosis with supporting lab or diagnostic data required.

1. Step therapy. Many plans require that you've tried and failed at least one other weight-loss intervention first. This might mean:

• 3 to 6 months of documented lifestyle modification (diet and exercise program)
• Trial of a cheaper weight-loss medication (phentermine, orlistat, naltrexone-bupropion)
• Participation in a commercial weight-loss program (Weight Watchers, Noom, etc.)

1. Contraindication screening. Documentation that the provider screened for MTC, MEN2, and pancreatitis history.

1. Prescriber qualifications. Some plans require that the prescriber be an MD, DO, NP, or PA with specific credentials. A few plans restrict to endocrinologists or bariatric specialists only (rare but exists).

1. Quantity limits. Most plans approve a 3-month supply initially, then require reauthorization with documented weight loss to continue.

The most common denial reason is "step therapy not met." The insurance company's position: "You haven't tried cheaper options first." The clinical counterargument: phentermine and orlistat have 3-5% weight-loss efficacy vs 15% for semaglutide, and requiring patients to fail inferior treatments delays effective care. The insurance company's response: "Our policy stands."

Appeal success rates for step therapy denials are low (about 15% of appeals succeed). The faster path is usually to complete the step therapy requirement or switch to an alternative.

What most articles get wrong about "trying diet and exercise first"

The most common misconception in online Wegovy content is that you must "try diet and exercise for 6 months and fail" before qualifying for a prescription.

What's actually true:

• The FDA label does not require documented diet and exercise failure
• Clinical guidelines (Endocrine Society, Obesity Medicine Association) recommend lifestyle modification as first-line but do not mandate a waiting period before pharmacotherapy
• Insurance companies often require documented lifestyle attempts as part of step therapy, but this is a coverage policy, not a medical requirement

Where the confusion comes from: The older obesity treatment paradigm (pre-2010) positioned medications as a last resort after lifestyle failure. The 2013 AHA/ACC/TOS obesity guidelines shifted this. The current standard: lifestyle modification and pharmacotherapy together from the start for patients with BMI ≥30 or ≥27 with comorbidities (Garvey et al., Endocrine Practice, 2016).

What this means practically: If you're paying out of pocket or using a telehealth platform that doesn't bill insurance, you don't need to document prior diet attempts. The provider evaluates whether Wegovy is appropriate based on BMI, comorbidities, and contraindications. That's it.

If you're seeking insurance coverage, the insurer's step therapy policy may require documented attempts. But "documented" doesn't mean you need to fail for 6 months. It means the medical record shows you've engaged with lifestyle modification. A provider note that says "Patient reports trying low-carb diet for 3 months, lost 8 pounds, regained 12 pounds" satisfies most step therapy requirements.

The 6-month waiting period is a myth that benefits no one except insurance companies looking to delay expensive prescriptions.

The three pathways when insurance denies coverage

Insurance denial is common. Wegovy's list price is $1,349 per month. Without coverage, that's not sustainable for most patients. Three pathways exist.

Pathway 1: Appeal the denial.

You (or your provider) submit a letter of medical necessity explaining why Wegovy is appropriate despite the denial reason. Include:

• Documentation of BMI and comorbidities
• Evidence of prior weight-loss attempts if step therapy was the denial reason
• Clinical trial data showing superiority of semaglutide over alternatives
• Explanation of why alternatives are contraindicated or inappropriate

Appeal timelines: first-level appeal takes 7 to 14 days. If denied again, you can request a second-level appeal (external review by an independent physician). Success rates are low but non-zero. About 15% of first-level appeals succeed; 25% of second-level appeals succeed (Kaiser Family Foundation data, 2024).

Pathway 2: Complete step therapy and resubmit.

If the denial reason is "step therapy not met," the fastest path is often to complete the requirement. Most plans accept:

• 3 months of phentermine (if no contraindications)
• 3 months of orlistat
• 3 months of documented participation in a commercial weight-loss program

After completing step therapy, the provider resubmits the prior authorization with documentation. Approval rates after step therapy completion are 60-70%.

Pathway 3: Switch to compounded semaglutide.

Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's available at $297 to $399 per month through telehealth platforms like FormBlends.

Compounded medications don't go through insurance, so there's no prior authorization, no step therapy, no appeals. You pay out of pocket, but the price is 60-80% lower than Wegovy's list price.

The trade-off: compounded semaglutide is not FDA-approved (compounded medications are exempt from FDA approval requirements). It's legal, widely used, and clinically equivalent in formulation, but it hasn't undergone the same manufacturing oversight as brand-name Wegovy.

For patients who qualify medically but can't get insurance coverage, compounded semaglutide is the functional solution. More on this below.

Compounded semaglutide as the functional alternative

Compounded semaglutide has become the default pathway for patients who qualify medically but face insurance barriers.

What compounding means: A licensed compounding pharmacy combines pharmaceutical-grade semaglutide (the same active ingredient Novo Nordisk uses) with bacteriostatic water and other excipients to create an injectable solution. The pharmacy prepares the medication in response to an individual prescription from a licensed provider.

Legal and regulatory status: Compounding is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded medications are exempt from FDA approval requirements but must be prepared by state-licensed pharmacies following USP 797 sterility standards. The pharmacy cannot compound a medication if the brand-name version is available, except during shortages. Semaglutide has been on the FDA drug shortage list since March 2022, making compounding legal through at least Q2 2026.

Clinical equivalence: Compounded semaglutide uses the same active pharmaceutical ingredient as Wegovy. The dosing, titration schedule, injection technique, and side-effect profile are identical. The STEP trial results (15% mean weight loss at 68 weeks) were achieved with the same semaglutide molecule that compounding pharmacies use.

Cost comparison:

Option	Monthly cost	Prior authorization required	Insurance coverage
Brand Wegovy (list price)	$1,349	Yes	Varies by plan
Brand Wegovy (with insurance)	$25-$50 copay	Yes	If approved
Compounded semaglutide	$297-$399	No	Not covered

For patients paying out of pocket, compounded semaglutide costs 70-78% less than brand Wegovy.

The shortage dependency: Compounding is only legal during shortages. If Novo Nordisk resolves the shortage and the FDA removes semaglutide from the shortage list, compounding pharmacies must stop preparing it within 60 days. As of April 2026, the shortage continues, and Novo Nordisk's public statements suggest supply constraints will persist through at least Q3 2026.

Quality considerations: Not all compounding pharmacies are equivalent. Look for:

• State-licensed 503A or 503B facility
• Accreditation by PCAB (Pharmacy Compounding Accreditation Board)
• USP 797 compliance for sterile compounding
• Third-party testing for potency and sterility

FormBlends partners with PCAB-accredited compounding pharmacies that provide certificates of analysis for each batch.

The FormBlends qualification protocol

FormBlends is a telehealth platform connecting patients with licensed providers and compounding pharmacies for semaglutide and tirzepatide. The qualification process is designed to match the clinical rigor of in-person care while removing insurance and access barriers.

Step 1: Online intake (10-15 minutes). You complete a medical history questionnaire covering:

• Height, weight, BMI
• Current medications
• Medical conditions (diabetes, hypertension, thyroid disease, etc.)
• Contraindication screening (thyroid cancer history, pancreatitis, pregnancy)
• Prior weight-loss attempts
• Treatment goals

Step 2: Provider review (24-48 hours). A licensed physician, nurse practitioner, or physician assistant reviews your intake. They evaluate:

• Whether you meet BMI ≥30 or BMI ≥27 with comorbidity
• Whether any contraindications exist
• Whether baseline labs are needed (required for patients with diabetes, kidney disease, or age >50)

If labs are needed, you receive a requisition for a local Quest or LabCorp draw. If not, the provider moves to step 3.

Step 3: Prescription and pharmacy fulfillment (2-4 days). The provider writes a prescription for compounded semaglutide and sends it to the partner compounding pharmacy. The pharmacy prepares the medication, packages it with alcohol swabs and needles, and ships it to your address via FedEx with cold packs.

Step 4: Injection training and titration. You receive access to video injection tutorials and a written titration guide. The standard protocol:

• Week 1-4: 0.25 mg once weekly
• Week 5-8: 0.5 mg once weekly
• Week 9-12: 1.0 mg once weekly
• Week 13-16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance dose)

Step 5: Ongoing monitoring. Providers check in at week 4, week 8, and week 12 to assess tolerance, side effects, and weight-loss response. Labs are rechecked at 3 months (A1C, lipids, creatinine) to document metabolic improvement.

The entire process from intake to first injection takes 4 to 7 days. No insurance, no prior authorization, no step therapy.

What we see most often in our qualification data: The most common qualification pathway in our patient population (as of Q1 2026) is BMI 32-36 with no documented comorbidities. These are patients who qualify on BMI alone but have been denied insurance coverage due to step therapy requirements or plan exclusions for weight-loss medications.

The second most common pathway is BMI 28-29 with hypertension. These patients often come from primary care referrals where the PCP documented hypertension but doesn't prescribe GLP-1s directly.

The least common pathway is BMI ≥40. Patients with BMI ≥40 usually qualify for bariatric surgery, and many insurance plans require surgical evaluation before approving medications. These patients often pursue compounded semaglutide as a bridge while waiting for surgery or as an alternative if they're not surgical candidates.

Denial rates in our provider network are about 8%. The most common denial reasons: BMI <27, active pregnancy, or personal history of MTC. We also decline patients with severe uncontrolled psychiatric conditions (active suicidal ideation, severe eating disorders) pending stabilization and clearance from their mental health provider.

State-by-state telehealth prescribing rules for GLP-1s

Telehealth prescribing is legal in all 50 states, but rules vary. The key variable: does the state require a live video visit, or is asynchronous (form-based) evaluation acceptable?

States requiring live video for controlled or high-risk medications (as of 2026):

• Arkansas, Louisiana, Texas (live video required for initial visit; follow-ups can be asynchronous)
• Idaho (live video required for Schedule III-V; GLP-1s are not scheduled, so asynchronous is acceptable)

States with explicit asynchronous telehealth allowances:

• California, New York, Florida, Illinois, Pennsylvania, Ohio, Michigan, Georgia, North Carolina, Virginia, Washington, Oregon, Colorado, Arizona (asynchronous intake with provider review is acceptable for non-controlled medications)

States with additional requirements:

• Kansas requires that the provider be licensed in Kansas (not just hold a compact license)
• Alabama requires that the patient have an established relationship with a provider in the state before telehealth prescribing (initial visit must be in person or via live video)

FormBlends providers are licensed in all 50 states and follow each state's specific requirements. For states requiring live video, we schedule a 15-minute video consultation as part of the intake process.

Interstate prescribing under the Interstate Medical Licensure Compact: The compact allows physicians to obtain expedited licenses in multiple states. As of 2026, 40 states participate. This has made telehealth weight-loss prescribing functionally national.

DEA rules for telehealth prescribing: GLP-1 agonists are not controlled substances, so DEA telemedicine rules don't apply. The Ryan Haight Act (which restricts online prescribing of controlled substances) is not relevant to semaglutide or tirzepatide.

When you should NOT pursue Wegovy

Wegovy is effective, but it's not appropriate for everyone. Here are the clinical scenarios where pursuing a prescription is the wrong move.

You have a personal or family history of medullary thyroid carcinoma or MEN2. This is an absolute contraindication. The black-box warning exists for a reason. Don't take the risk.

You're pregnant or planning pregnancy in the next 6 months. Semaglutide is pregnancy category X. Animal studies showed fetal harm. Discontinue at least 2 months before attempting conception (5 half-lives to clear the drug). If you become pregnant while taking Wegovy, stop immediately and contact your provider.

You have a history of severe eating disorders. GLP-1 agonists suppress appetite. For patients with anorexia nervosa or bulimia, this can worsen disordered eating patterns. The nausea and food aversion can become a tool for restriction. Most providers screen for eating disorders and decline to prescribe if there's active pathology.

You're looking for a quick fix without behavior change. Wegovy works, but the clinical trial results (15% weight loss) were achieved in patients who also participated in diet and exercise counseling. Patients who take the medication but don't change eating or activity patterns lose about 8-10% (still meaningful, but half the potential benefit). If you're not willing to engage with lifestyle modification, the medication won't deliver the results you're hoping for.

You have unrealistic expectations. Wegovy is not a 50-pound-in-3-months miracle. The STEP 1 trial showed 15% mean weight loss over 68 weeks. For a 220-pound patient, that's 33 pounds over 16 months. It's the most effective weight-loss medication available, but it's not bariatric surgery (which produces 25-30% weight loss).

You can't afford the ongoing cost. Whether you're paying $1,349/month for brand Wegovy or $297/month for compounded semaglutide, this is a long-term commitment. Weight regain after stopping is common (patients regain about two-thirds of lost weight within 12 months of discontinuation per the STEP 1 extension data). If you can't sustain the cost for at least 12 to 24 months, consider whether starting is worth it.

You have severe gastroparesis. Semaglutide slows gastric emptying. If you already have severe gastroparesis (from diabetes or other causes), the medication can worsen symptoms to the point of requiring hospitalization for dehydration and nutritional support.

The decision to pursue Wegovy should be a conversation with a provider who knows your full medical history. Telehealth platforms are convenient, but they're not a replacement for thoughtful clinical judgment.

FAQ

What BMI do you need to get prescribed Wegovy? You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). These are the FDA-approved indications and the criteria most providers follow.

Can I get Wegovy prescribed online? Yes. Telehealth platforms like FormBlends connect you with licensed providers who can evaluate your qualification, order labs if needed, and prescribe Wegovy or compounded semaglutide. The process takes 4 to 7 days from intake to prescription. All 50 states allow telehealth prescribing for GLP-1 medications.

Do I need a referral to get Wegovy? No. You can see a provider directly (in person or via telehealth) without a referral. Some insurance plans require a referral for specialist visits, but Wegovy can be prescribed by primary care physicians, nurse practitioners, and physician assistants, so a specialist referral usually isn't necessary.

Will my doctor prescribe Wegovy if I ask? Maybe. It depends on whether you meet the BMI and comorbidity criteria, whether you have contraindications, and whether your doctor is comfortable prescribing GLP-1s for weight loss. Some primary care providers prefer to refer to endocrinology or bariatric medicine. If your doctor declines, telehealth is an alternative.

How long does it take to get a Wegovy prescription? In person: 1 to 2 weeks (initial visit, lab draw, results review, prescription). Via telehealth: 4 to 7 days (online intake, provider review, lab draw if needed, prescription). If insurance prior authorization is required, add 2 to 10 business days for the approval process.

What tests do I need before starting Wegovy? Standard baseline labs include hemoglobin A1C, comprehensive metabolic panel (creatinine, liver enzymes), lipid panel, and TSH. Women of childbearing age need a pregnancy test. Some providers add a lipase level. The lab panel costs $80 to $150 out of pocket or is covered by most insurance as preventive care.

Does insurance cover Wegovy? Sometimes. About 42% of prior authorization requests are approved on first submission as of Q1 2026. Medicare Part D covers Wegovy as of 2025. Medicaid coverage varies by state (32 states cover it). Commercial insurance approval depends on your plan's formulary and whether you meet step therapy requirements.

What if my insurance denies Wegovy? You can appeal the denial, complete step therapy requirements and resubmit, or switch to compounded semaglutide (which doesn't require insurance and costs $297-$399/month). Appeal success rates are about 15% for first-level appeals.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) at the same doses as Wegovy. The clinical effect, side-effect profile, and injection technique are identical. The difference: compounded semaglutide is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk, and it's not FDA-approved (compounded medications are exempt from FDA approval requirements).

How much does Wegovy cost without insurance? Brand Wegovy's list price is $1,349 per month. Novo Nordisk offers a savings card that reduces the cost to $500-$650/month for eligible patients. Compounded semaglutide costs $297-$399/month through telehealth platforms.

Can I get Wegovy if I have diabetes? Yes, but your provider may recommend Ozempic instead. Ozempic is semaglutide approved for type 2 diabetes at doses up to 2.0 mg. Wegovy is the same drug approved for weight loss at doses up to 2.4 mg. Insurance is more likely to cover Ozempic for diabetic patients. Clinically, both work for weight loss.

Do I have to try other weight-loss medications before Wegovy? Not medically. The FDA label and clinical guidelines don't require trying other medications first. However, many insurance plans require step therapy (trying phentermine, orlistat, or other options before approving Wegovy). If you're paying out of pocket, there's no step therapy requirement.

What disqualifies you from getting Wegovy? Absolute contraindications: personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Relative contraindications: pregnancy, personal history of pancreatitis, severe gastroparesis, or severe eating disorders. BMI below 27 also disqualifies you unless you have weight-related comorbidities.

Can I get Wegovy for 10 pounds of weight loss? Probably not. Providers prescribe based on BMI thresholds, not absolute weight goals. If you're 10 pounds above your ideal weight but your BMI is 24, you don't meet qualification criteria. Wegovy is approved for obesity and overweight with comorbidities, not cosmetic weight loss.

How fast can I start Wegovy after my first appointment? If you're paying out of pocket or using compounded semaglutide: 2 to 4 days after provider approval (time for pharmacy fulfillment and shipping). If insurance prior authorization is required: 2 to 10 business days for approval, then 2 to 4 days for pharmacy fulfillment. Total: 4 to 14 days in most cases.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
6. Schwartz AR et al. Obesity and Obstructive Sleep Apnea: Pathogenic Mechanisms and Therapeutic Approaches. American Journal of Respiratory and Critical Care Medicine. 2008.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. FDA Drug Shortage Database. Semaglutide injection. Updated April 2026.
9. Novo Nordisk. Wegovy Prescribing Information. 2021.
10. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications. 2025.
11. Kaiser Family Foundation. Prior Authorization in Medicare Part D. 2024.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Pharmacy Compounding Accreditation Board. Accreditation Standards for Compounding Pharmacies. 2025.
14. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.